OsteoArthritis Centers of America and Gensco Laboratories are collaborating on a research study to better OA Centers of America's proprietary algorithm for treating pain conditions.
Here are four things to know:
1. OsteoArthritis will use Gensco's patented Transdermal products as an additional option to demonstrate improved patient outcomes.
2. The product will also add economic value of treating pain with transdermal technology.
3. The research collaboration will work on providing a non-narcotic pain control option for patients.
4. Carlos Alfaras, president and CEO of Gensco Labs, is confident the partnership will yield successful results due to OA Center of America's expertise in treating patients with osteoarthritis and musculoskeletal pain.
For more on practice management:
5 things to know about Lemak Health opening a new sports medicine clnic
5 areas of focus to improve your patient acquisition through online marketing
Second opinions often result in dianosis or treatment changes — 5 key points